Cancer – ADVL1521: Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Condition or Therapy:
Juvenile myelomonocytic leukemia
What is the goal of this study?
This phase II trial stuides how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are 1 month to 21 years old
- Have had relapsed or refractory juvenile myelomonocytic leukemia
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.